Reshaping the Pharma Industry

The video discusses the impact of Brexit on the pharmaceutical industry, highlighting that the main effect is on foreign exchange translations rather than R&D spending. It explores the importance of R&D productivity, noting a positive cycle with numerous new product launches. The convergence of pharma and biotech industries is examined, with Bristol Myers leading in Immuno-Oncology. Political risks, particularly drug pricing, are analyzed, with pressure from both political rhetoric and the private sector. The global pharmaceutical market is discussed, emphasizing pricing differences between the US and Europe. Finally, Pfizer's strategic decisions, including a potential breakup, are covered.

What role does political risk play in the pharmaceutical industry according to the discussion?

How do global pharmaceutical companies affect drug pricing in different countries?

What are the potential consequences of Pfizer's decision to break up or not?